跳至主要内容
临床试验/ACTRN12611000497909
ACTRN12611000497909已完成4 期

A randomised double-blind placebo-controlled trial to investigate whether paracetamol lengthens the duration of viral shedding in the treatment of patients with influenza

Medical Research Institute of New Zealand0 个研究点目标入组 80 人开始时间: 2011年5月12日最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • Onset of an influenza like illness in the past 48 hours: history of fever or documented temperature greater than or equal to 37.8 degree celsius, and at least one of cough, sore throat, rhinorrhea, headache, myalgia, fatigue, or malaise

排除标准

  • Influenza illness severe enough to warrant hospital admission.
  • A history of allergy or sensitivity or other contraindication to paracetamol or opiates.
  • Subjects using paracetamol or NSAIDS (not including low dose aspirin) regularly who are unwilling or unable to discontinue use during the trial period.
  • Recent treatment with oseltamivir.
  • HIV infection.
  • Current pregnancy.
  • Current treatment with oral corticosteroids or other immunosuppressant drugs.
  • Any other safety concern at the investigator’s discretion.

研究者

相似试验